Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Adverum Biotechnologies, Inc. | d506758d8k.htm |
Exhibit 16.1
January 23, 2018
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549-7581
Dear Sirs/Madams:
We have read Item 4.01 of Adverum Biotechnologies Inc.’s Form 8-K dated January 26, 2018, and have the following comments:
| 1. | We agree with the statements made in the second sentence of paragraph 2, and the statements made in paragraphs 3, 4 and 5. |
| 2. | We have no basis on which to agree or disagree with the statements made in paragraphs 1 and 6 and the statements made in the first sentence to paragraph 2. |
Yours truly,
/s/ Deloitte & Touche LLP
San Jose, CA